Dermatology News

Dermatology

sponsor
Become a Member Today!
Register
Email:


Password:

Remember me
Forgot your Password?
Invite Code?
Article ID

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Ferraldeschi R et al. - Activation of angiogenesis is a necessary condition for tumor growth and metastatic dissemination of solid tumors. Numerous anti-angiogenic agents for the treatment of melanoma are currently in clinical trials or in development. A number of early-phase clinical trials have been completed and studies investigating combinations of targeted agents or combining treatment with chemotherapy are ongoing.

Related Articles

Loss of SNF5 expression correlates with poor patient survival in melanoma
Clinical Cancer Research, 10/12/09    Relevance Score: 97%

Slow-growing melanoma: a dermoscopy follow-up study
British Journal of Dermatology, 10/05/09    Relevance Score: 93%

Dormancy of metastatic melanoma
Pigment Cell & Melanoma Research, 11/11/09    Relevance Score: 91%

ADAM10 Is Upregulated in Melanoma Metastasis Compared with Primary Melanoma
Journal of Investigative Dermatology, 11/03/09    Relevance Score: 91%

KIT as a Therapeutic Target in Melanoma
Journal of Investigative Dermatology, 10/23/09    Relevance Score: 90%

Today in Dermatologic Oncology...keeping you current

Evaluation of EMMPRIN and MMP-2 in the prognosis of primary cutaneous malignant melanoma
Medical Oncology, 12/03/09

Cutaneous lymphangioma circumscriptum: frog spawn on the skin
International Journal of Dermatology, 12/03/09

Melanoma incidence and exposure to angiotensin-converting enzyme inhibitors and angiotensin receptor blockers
Cancer Epidemiology, 12/03/09


Sponsor

Article Search

Keyword:

Search:

Published within

Sort By:
Date
Relevance


Sponsor

Send this Summary to a Colleague

Enter email address